Merck and Moderna are making headlines after their personalized mRNA cancer vaccine entered Phase 3 clinical trials for melanoma. For most people, it is an exciting medical story. For the synovial sarcoma community, it is something more personal than that. What the Vaccine Is mRNA-4157, combined with Merck’s immunotherapy pembrolizumab, works by sequencing a patient’s […]
World’s First MAGE-A4-Targeting TCR-NK Therapy Zelluna Doses First Patient in Clinical Trial
Zelluna ASA, a Norwegian biotech company pioneering allogeneic cell therapies for solid cancers, recently announced that the first patient has received the first dose of ZI-MA4-1 in the ZIMA-101 Phase 1 clinical trial. The treatment was administered at The Christie NHS Foundation Trust in Manchester, United Kingdom, the largest single-site cancer centre in Europe, marking […]


